市場調査レポート
商品コード
1082943
乳腺嚢胞治療の世界市場:2022年~2029年Global Breast Cyst Treatment Market - 2022-2029 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
乳腺嚢胞治療の世界市場:2022年~2029年 |
出版日: 2022年06月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
|
当レポートでは、世界の乳腺嚢胞治療の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、アンメットニーズ、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
The global breast cyst treatment market is growing at a high CAGR during the forecast period (2022-2029).
Inside the breast, cysts are fluid-filled sacs. They are usually cancer-free (benign). Breast cysts can be single or multiple. A breast cyst feels like a grape or a water-filled balloon most of the time, but it can also be firm.
The factors influencing the global breast cyst treatment market are the increasing research and development and the growing prevalence of breast cysts.
The increasing research and development are expected to drive the market growth
Cysts appear to form due to fibrosis in the development of breast tissue and subsequent failure of the lobule and terminal ductule formation process. The physical mechanism is that fibrosis causes epithelial thickening, which causes the developing lobule to be involute early in its development. This causes the surrounding stroma to vanish and the adjoining ductule to collapse, resulting in an abnormal epithelial-lined fold that becomes completely walled off. Epithelial acinar secretions dilate the epithelial fold, transforming it into a self-contained fluid-filled cavity. Moreover, many studies show a high lifetime prevalence of fibrocystic breast disease in women. Over 70% of all women experience fibrocystic changes at some point in their lives, with 20% of these women becoming symptomatic and 10% -30% developing sclerosing adenosis. A palpable breast cyst is estimated to affect 7% of all women in the United States at some point in their lives. Breast cysts are most common in women aged 30 to 50. During these years, the incidence of cyst development rises and then falls dramatically. Most benign cysts disappear, and new cysts stop developing a year after menopause, as cyst development is linked to hormone levels in the body.
Limitations associated with breast cyst treatment are expected to hamper the market growth
The risks associated with Fine Needle Aspiration are minimal. The injection site has a small chance of bleeding and infection. The patient may be sore for a day or two after the procedure, and mild bruising and swelling may occur. Another disadvantage of fine needle aspiration is that the needle may miss a tumor and instead take a sample of healthy cells.
If this occurs, the biopsy will show that cancer does not exist when it does. A false negative result causes a delay in diagnosis. Fine needle aspirations of palpable lumps have a 2-4 percent low false-negative rate.
COVID-19 Impact Analysis
The market has suffered a minor setback due to the COVID-19 outbreak, owing to delays in diagnosis, drug shortages, and a lack of healthcare professionals. According to an article published in the JAMA Network in August 2020, between March 1, 2020, and April 18, 2020, there was a significant decrease in breast cancer treatment and diagnosis in the United States (by as much as 51.8 percent). As a result, the delay in diagnosing breast cancer has impacted treatment. In its early stages, the COVID-19 pandemic has had a negative impact on the breast cyst treatment market. However, as treatments are resumed worldwide, the market is expected to gain traction in the coming years.
Fine-needle aspiration segment is expected to dominate the market growth
If all the fluid in the cyst can be removed during the procedure, fine-needle aspiration can be used to diagnose and treat a breast cyst, and breast lump and symptoms disappear. However, some breast cysts may require more than one drainage procedure. Cysts that recur or form new cysts are common. If a breast cyst persists for two to three menstrual cycles and grows, it should be treated. A small amount of breast tissue or fluid is removed from a suspicious area with a thin, hollow needle and checked for cancer cells during a fine needle aspiration (FNA). If other tests indicate that you may have breast cancer, this type of biopsy may be an option (although a core needle biopsy is often preferred). lt can also be used in other contexts. The main benefits of FNA are that it is relatively quick, it rarely requires anesthesia, the skin is not cut, so no stitches are required, and there is usually no scar. In some cases, one can even get the results on the same day.
Moreover, on 20th April 2020, The FDA-approved Fisher's CytoCore fine needle device, which can be attached to a small needle, has an internal motor that rotates the needle during the biopsy.
North America region is expected to hold the largest market share in the global breast cyst treatment market
The growing incidence of breast cysts and increasing research and development in this region is expected to drive the market growth in the forecast period.
A palpable breast cyst is estimated to affect 7% of all women in the United States at some point in their lives. Breast cysts are most common in women aged 30 to 50. Moreover, key players in this region are expected to drive market growth. For instance, Becton, Dickinson, and Company, or BD, is a multinational medical technology company based in the United States. The company's FNA needles are available with a Chiba or Franseen tip for maximum versatility when aspirating soft tissue masses.
The global breast cyst treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Advin Health Care, Becton, Dickinson, and Company, Swastik Enterprise, Argon Medical Devices, Inc., SOMATEX Medical Technologies GmbH, Remington Medical Inc., HAKKO CO., LTD., BPB MEDICA
Becton, Dickinson, and Company
Overview: Becton, Dickinson, and Company, or BD, is a multinational medical technology company based in the United States that manufactures and sells medical devices, instrument systems, and reagents. In some areas, BD also offers consulting and analytics services.
Product Portfolio: The company's FNA needles are available with a Chiba or Franseen tip for maximum versatility when aspirating soft tissue masses.
The global breast cyst treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.
LIST NOT EXHAUSTIVE